BeOne Medicines AG (HKG:6160)

Market Cap	262.26B +23.9%
Revenue (ttm)	41.59B +40.2%
Net Income	2.23B
EPS	19.23
Shares Out	n/a
PE Ratio	117.43
Forward PE	52.01
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,484,350
Average Volume	3,654,576
Open	182.10
Previous Close	178.90
Day's Range	181.20 - 185.80
52-Week Range	115.80 - 229.40
Beta	0.52
RSI	39.66
Earnings Date	Feb 26, 2026

About BeOne Medicines AG

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients w...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 12,000
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6160

Financial Performance

Financial numbers in USD